JP2003517580A5 - - Google Patents

Download PDF

Info

Publication number
JP2003517580A5
JP2003517580A5 JP2000595151A JP2000595151A JP2003517580A5 JP 2003517580 A5 JP2003517580 A5 JP 2003517580A5 JP 2000595151 A JP2000595151 A JP 2000595151A JP 2000595151 A JP2000595151 A JP 2000595151A JP 2003517580 A5 JP2003517580 A5 JP 2003517580A5
Authority
JP
Japan
Prior art keywords
gdf
activity
inhibitor
protein
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000595151A
Other languages
English (en)
Other versions
JP2003517580A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/001552 external-priority patent/WO2000043781A2/en
Publication of JP2003517580A publication Critical patent/JP2003517580A/ja
Publication of JP2003517580A5 publication Critical patent/JP2003517580A5/ja
Pending legal-status Critical Current

Links

Description

【特許請求の範囲】
【請求項1】 (a)GDFタンパク質を生産する細胞を培養した培地を得る
こと;(b)GDF活性を阻害する能力に関して該培地を試験し、それによりGDFイ
ンヒビターを同定すること:
を含んでなる、GDFタンパク質のインヒビターの同定方法。
【請求項2】 (a)GDFタンパク質のフラグメントを調製すること;(
b)GDF活性を阻害する能力に関して該フラグメントを試験し、それによりGDFイ
ンヒビターを同定すること:
を含んでなる、GDFタンパク質のインヒビターの同定方法。
【請求項3】 ヒトGDF-8またはGDF-11をコードするインサートを含有す
る発現プラスミドで安定にトランスフェクションしたCHO細胞を単離した培地か
らイオン交換クロマトグラフィーにより単離することができ、100℃で10分まで
の間加熱した後に活性を保持し、還元後に活性を保持し、そして6M尿素での処理
後に活性を保持するGDF-8またはGDF-11インヒビター。
【請求項4】 ヒトGDF-8またはGDF-11をコードするインサートを含有す
る発現プラスミドで安定にトランスフェクションしたCHO細胞を単離した培地か
らイオン交換クロマトグラフィーにより単離することができ、100℃で10分まで
の間加熱した後に活性を保持し、還元後に活性を失い、そして6M尿素での処理後
に活性を保持するGDF-8またはGDF-11インヒビター。
【請求項5】 GDF活性を阻害するGDFタンパク質またはペプチド。
【請求項6】 GDFタンパク質のプロ-ドメインまたはプロ-ドメインの一
部を含んでなるGDFインヒビター。
【請求項7】 細胞にトランスフェクションするとGDF発現を阻害する、
配列番号:1、2、3及び4よりなる群から選択されるヌクレオチド配列を含んでな
る単離された核酸。
【請求項8】 細胞にトランスフェクションするとGDF発現を阻害する、
配列番号:5-24よりなる群から選択されるヌクレオチド配列を含んでなる単離さ
れた核酸。
【請求項9】 GDFタンパク質の変異体を含んでなるGDFインヒビター。
【請求項10】 細胞におけるGDF活性を阻害する、配列番号:25、29また
は30よりなる群から選択されるアミノ酸配列を含んでなる単離されたポリペプチ
ド。
【請求項11】 GDFインヒビターを発現する非ヒト動物。
JP2000595151A 1999-01-21 2000-01-21 増殖分化因子インヒビター及びそれらの用途 Pending JP2003517580A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11663999P 1999-01-21 1999-01-21
US60/116,639 1999-01-21
US13836399P 1999-06-10 1999-06-10
US60/138,363 1999-06-10
PCT/US2000/001552 WO2000043781A2 (en) 1999-01-21 2000-01-21 Growth differentiation factor inhibitors and uses therefor

Publications (2)

Publication Number Publication Date
JP2003517580A JP2003517580A (ja) 2003-05-27
JP2003517580A5 true JP2003517580A5 (ja) 2007-03-08

Family

ID=26814445

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000595151A Pending JP2003517580A (ja) 1999-01-21 2000-01-21 増殖分化因子インヒビター及びそれらの用途

Country Status (12)

Country Link
EP (1) EP1147413B1 (ja)
JP (1) JP2003517580A (ja)
CN (1) CN100567322C (ja)
AT (1) ATE322681T1 (ja)
AU (2) AU772694B2 (ja)
BR (1) BR0008188A (ja)
CA (1) CA2359242C (ja)
DE (1) DE60027135T2 (ja)
HK (1) HK1041521B (ja)
MX (1) MXPA01007366A (ja)
NZ (1) NZ513642A (ja)
WO (1) WO2000043781A2 (ja)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393682B1 (en) * 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US7037501B2 (en) 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
TW200526779A (en) * 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
EP1790726B1 (en) * 2001-02-08 2013-07-03 Wyeth LLC Modified and stabilized GDF propeptides and uses thereof
US6734289B2 (en) 2001-03-29 2004-05-11 The University Of Chicago Gastrokines and derived peptides including inhibitors
US7629317B2 (en) 2001-03-29 2009-12-08 The University Of Chicago Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors
DK1714982T3 (da) 2001-06-05 2009-05-04 Genetics Inst Llc Fremgangsmåde til rensning af stærkt anioniske proteiner
US20040248121A1 (en) * 2001-07-11 2004-12-09 Ravi Kambadur Bioassay for myostatin
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
BR0307907A2 (pt) 2002-02-21 2011-07-05 Wyeth Corp gasp1: proteìna contendo domìnio de folistatina
CA2476654A1 (en) 2002-02-21 2003-09-04 Wyeth Follistatin domain containing proteins
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
WO2004058988A2 (en) 2002-12-20 2004-07-15 Amgen, Inc. Binding agents which inhibit myostatin
WO2004108157A2 (en) 2003-06-02 2004-12-16 Wyeth Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
CA2561317A1 (en) 2004-03-26 2005-10-13 Acceleron Pharma Inc. Bmp-3 propeptides and related methods
JP4688483B2 (ja) * 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
WO2005113590A2 (en) 2004-05-12 2005-12-01 Acceleron Pharma Inc. Bmp10 propeptides and related methods
AU2005258286A1 (en) 2004-06-24 2006-01-05 Acceleron Pharma Inc. GDF3 propeptides and related methods
JP2008507288A (ja) 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ActRII受容体ポリペプチド、方法、および組成物
JP2008506787A (ja) * 2004-07-29 2008-03-06 シェーリング−プラウ・リミテッド 動物においてミオスタチン活性を調節または阻害して赤身組織の成長増加を導くalk5インヒビターの使用
AU2006226878A1 (en) * 2005-03-23 2006-09-28 Wyeth Detection of GDF-8 modulating agents
EP1864139A2 (en) * 2005-03-23 2007-12-12 Wyeth Detection of an immune response to gdf-8 modulating agents
US8017576B2 (en) 2005-05-10 2011-09-13 The University Of Chicago Methods and compositions to treat mucositis
SI1915397T1 (sl) 2005-08-19 2015-05-29 Wyeth Llc Antagonistična protitelesa proti GDF-8 in uporabe pri zdravljenju ALS in drugih obolenj, povezanih z GDF-8
US7635760B2 (en) 2005-10-06 2009-12-22 Eli Lilly And Company Anti-myostatin antibodies
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
KR20160137665A (ko) 2005-11-23 2016-11-30 악셀레론 파마 인코포레이티드 액티빈-actrⅱa 길항제 및 골 성장을 촉진하기 위한 이들의 용도
PT2066695E (pt) 2006-09-05 2013-05-23 Lilly Co Eli Anticorpos anti-miostatina
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
NZ707292A (en) 2006-12-18 2017-06-30 Acceleron Pharma Inc Activin-actrii antagonists and uses for increasing red blood cell levels
MX354099B (es) 2007-02-01 2018-02-13 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
DK2120999T3 (da) 2007-02-09 2012-12-03 Acceleron Pharma Inc Farmaceutiske sammensætninger omfattende Activin-ActRIIA antagonister samt anvendelse deraf ved forebyggelse eller behandling af multipelt myelom
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
US9610327B2 (en) 2007-03-06 2017-04-04 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
EP3243524A1 (en) 2007-09-18 2017-11-15 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
KR100857861B1 (ko) * 2007-10-15 2008-09-11 주식회사 바이오리더스 Myo-2 펩타이드 중합체와 마이오스타틴의 융합단백질표면발현용 벡터 및 상기 벡터로 형질전환된 미생물
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
TW201919685A (zh) 2008-08-14 2019-06-01 美商艾瑟勒朗法瑪公司 使用gdf阱以增加紅血球水平
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
PE20120206A1 (es) 2008-11-26 2012-03-09 Amgen Inc Variantes de polipeptidos receptores de activina iib
EP2387412A4 (en) 2009-01-13 2013-04-03 Acceleron Pharma Inc METHODS FOR INCREASING ADIPONECTIN
MX2011013172A (es) 2009-06-08 2012-04-02 Acceleron Pharma Inc Metodos para aumentar adipocitos termogenicos.
KR20120028358A (ko) 2009-06-12 2012-03-22 악셀레론 파마 인코포레이티드 절두된 ActRIIB-FC 융합 단백질
MX2012001916A (es) 2009-08-13 2012-05-22 Acceleron Pharma Inc Uso combinado de trampas gdf y activadores de receptor de eritropoyetina para incrementar los niveles de globulos rojos.
EP2483300A4 (en) * 2009-10-01 2013-02-27 Covita Ltd SYNTHETIC PEPTIDE ANTAGONISTS OF MYOSTATIN
WO2011056896A1 (en) 2009-11-03 2011-05-12 Acceleron Pharma Inc. Methods for treating fatty liver disease
JP6267425B2 (ja) 2009-11-17 2018-01-24 アクセルロン ファーマ, インコーポレイテッド 筋ジストロフィー治療のためのユートロフィン誘導に関するactriibタンパク質およびその改変体およびその使用
JP2014502260A (ja) 2010-11-08 2014-01-30 アクセルロン ファーマ, インコーポレイテッド Actriia結合剤およびその使用
WO2013059347A1 (en) 2011-10-17 2013-04-25 Acceleron Pharma, Inc. Methods and compositions for treating ineffective erythropoiesis
SG11201408042YA (en) 2012-06-15 2015-01-29 Pfizer Improved antagonist antibodies against gdf-8 and uses therefor
CA2880649C (en) 2012-08-01 2023-03-14 Elizabeth MCNALLY Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4)
BR112015007182A2 (pt) 2012-10-05 2017-07-04 Rigel Pharmaceuticals Inc inibidores de gdf-8
KR20220156979A (ko) 2012-11-02 2022-11-28 셀진 코포레이션 골 및 다른 장애를 치료하기 위한 액티빈-actrii 길항제 및 용도
AU2014212014A1 (en) 2013-02-01 2015-08-27 Amgen Inc. Administration of an anti-activin-A compound to a subject
DK2981822T3 (da) 2013-05-06 2020-12-07 Scholar Rock Inc Sammensætninger og fremgangsmåder til vækstfaktormodulation
AU2015247459A1 (en) 2014-04-18 2016-10-27 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating sickle-cell disease
KR102132144B1 (ko) 2014-06-04 2020-07-09 악셀레론 파마 인코포레이티드 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물
CN107135646B (zh) 2014-06-13 2022-03-15 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
US10696693B2 (en) 2014-11-21 2020-06-30 Rigel Pharmaceuticals, Inc. Fused imidazole derivatives as TGF-beta inhibitors
US11471510B2 (en) 2014-12-03 2022-10-18 Celgene Corporation Activin-ActRII antagonists and uses for treating anemia
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
CN107531666A (zh) 2015-02-20 2018-01-02 里格尔药品股份有限公司 Gdf‑8抑制剂
MY186133A (en) 2015-03-02 2021-06-24 Rigel Pharmaceuticals Inc Tgf-? inhibitors
EP3283479B1 (en) 2015-04-01 2022-12-14 Rigel Pharmaceuticals, Inc. Tgf-beta inhibitors
WO2016160881A1 (en) 2015-04-01 2016-10-06 Rigel Pharmaceuticals, Inc. TGF-β INHIBITORS
CN115073610A (zh) 2015-04-06 2022-09-20 阿塞勒隆制药公司 Alk7:actriib异多聚体和其用途
PL3280727T3 (pl) 2015-04-06 2021-07-19 Acceleron Pharma Inc. Jednoramienne białka fuzyjne receptora typu I i typu II i ich zastosowania
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
CA2983440C (en) 2015-04-22 2024-03-12 Alivegen Usa Inc. Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
AU2016359695A1 (en) 2015-11-23 2018-06-14 Acceleron Pharma Inc. Methods for treating eye disorders
RS62011B1 (sr) 2016-07-15 2021-07-30 Acceleron Pharma Inc Kompozicije koje sadrže polipeptide actriia za upotrebu u lečenju plućne hipertenzije
EA201990226A1 (ru) 2016-07-27 2019-08-30 Акселерон Фарма Инк. Способы и композиции для лечения миелофиброза
CN110678195A (zh) 2016-10-05 2020-01-10 阿塞勒隆制药公司 ALK4:ActRIIB异多聚体及其用途
EP3523328A4 (en) 2016-10-05 2020-04-01 Acceleron Pharma Inc. ACTRIIB VARIANT PROTEINS AND USES THEREOF
JP2019529509A (ja) 2016-10-05 2019-10-17 アクセレロン ファーマ インコーポレーテッド 腎臓疾患を治療するための組成物および方法
EP3897689A1 (en) 2018-12-21 2021-10-27 Northwestern University Use of annexins in preventing and treating muscle membrane injury
US20220062299A1 (en) 2018-12-26 2022-03-03 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
CA3142918A1 (en) * 2019-06-26 2020-12-30 Knc Laboratories Co., Ltd. Nucleic acid drug suppressing production of myostatin gene mrna

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254678A (en) * 1987-12-15 1993-10-19 Gene Shears Pty. Limited Ribozymes
WO1994021681A1 (en) * 1993-03-19 1994-09-29 Johns Hopkins University School Of Medicine Growth differentiation factor-8
US5616466A (en) * 1993-11-05 1997-04-01 Cantor; Glenn H. Ribozyme-mediated inhibition of bovine leukemia virus
DK0776337T3 (da) * 1994-07-08 2005-12-12 Univ Johns Hopkins Med Vækstdifferentieringsfaktor-11
US6008434A (en) * 1994-07-08 1999-12-28 Johns Hopkins University School Of Medicine Growth differentiation factor-11 transgenic mice
US5674748A (en) * 1995-03-14 1997-10-07 Thomas Jefferson University Human cyclin-dependent kinase-like proteins and methods of using the same
US6124115A (en) * 1995-09-22 2000-09-26 Endorecherche Inc. Production and use of isolated type 5 17β-hydroxysteroid dehydrogenase
US5824519A (en) * 1995-11-08 1998-10-20 Medical University Of South Carolina Tissue-specific and target RNA-specific ribozymes
WO1998024925A1 (en) * 1995-11-08 1998-06-11 Medical University Of South Carolina Tissue specific and target rna-specific ribozymes as antimicrobial therapeutics against microbial pathogens
AU6274298A (en) * 1997-02-05 1998-08-25 Johns Hopkins University School Of Medicine, The Growth differentiation factor-8
NO971997D0 (no) * 1997-04-29 1997-04-29 Kjetil Tasken Bruk av immunmodulerende midler
DK2045322T3 (en) * 1997-07-14 2015-10-05 Université de Liège DOUBLE MUSCULAR FOR MAMMALS
AU8666398A (en) * 1997-08-01 1999-02-22 Johns Hopkins University School Of Medicine, The Methods to identify growth differentiation factor (gdf) receptors
US6369201B1 (en) * 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
EP1100887A4 (en) * 1998-07-28 2003-01-15 Univ Johns Hopkins Med GROWTH DIFFERENTIATION FACTOR 11

Similar Documents

Publication Publication Date Title
JP2003517580A5 (ja)
Platt Termination of transcription and its regulation in the tryptophan operon of E. coli
Szabo et al. Distinct protein forms are produced from alternatively spliced bicistronic glutamic acid decarboxylase mRNAs during development
Kirschner et al. Mouse models of altered protein kinase A signaling
Kunitomo et al. A zinc-finger protein, Rst2p, regulates transcription of the fission yeast ste11+ gene, which encodes a pivotal transcription factor for sexual development
Pérez et al. Occurrence of a LINE sequence in the 3′ UTR of the goat αs1-casein E-encoding allele associated with reduced protein synthesis level
JP2003527856A5 (ja)
Li et al. Cooperative effects of C/EBP-like and NF x B-like binding sites on rat serum amyloid A1 gene expression in liver cells
RU2012101276A (ru) Инсектицидные cry-токсины dig-11
NZ610301A (en) Enzymes for the treatment of lignocellulosics, nucleic acids encoding them and methods for making and using them
Ames et al. Methylation segments are not required for chemotactic signalling by cytoplasmic fragments of Tsr, the methyl‐accepting serine chemoreceptor of Escherichia coli
JP2001523947A (ja) テロメラーゼ逆転写酵素
Kim et al. Middle East respiratory syndrome-coronavirus infection into established hDPP4-transgenic mice accelerates lung damage via activation of the pro-inflammatory response and pulmonary fibrosis
JP2009525046A5 (ja)
CA3091912A1 (en) Methods and compositions for treating angelman syndrome
CA2302385A1 (en) Gene encoding .alpha.-subunit of rice anthranilate synthase and dna relating thereto
JP2009507474A5 (ja)
JP2002508662A (ja) ヒトテロメラーゼの触媒サブユニット並びにその診断的及び治療的使用
WO1999045125A3 (en) Methods and compositions for regulating cell death and enhancing disease resistance to plant pathogens
Parquet et al. Nucleotide sequence of the murF gene encoding the UDP-MurNAc-pentapeptide synthetase of Escherichia coli.
JP2008508888A (ja) 細胞活性化のための方法および組成物
AU2007208928A8 (en) Transgenic plant transformed with stress-responsive gene
DE50310378D1 (de) Neue selektionsverfahren
Imaizumi et al. Mutant mice lacking Crk-II caused by the gene trap insertional mutagenesis: Crk-II is not essential for embryonic development
Larkin et al. The second largest subunit of RNA polymerase II from Arabidopsis thaliana.